The Body Pharm Retatrutide 64 Pen is a 64 mg prefilled multi-dose research peptide marketed in the UAE as a triple GLP-1/GIP/glucagon receptor agonist for in vitro metabolic work. It differs from shorter formats, the HD 32 mg pen and HD Labs 10 mg vial, through a longer per-pen run that materially affects per-dose AED economics and longitudinal assay continuity. Fewer cartridge changes reduce lot-to-lot variability. No manufacturer IFU confirms mg/mL or mcg-per-click for this SKU as of 2026, so any per-actuation figure remains undocumented.
The clinical backdrop matters here. Eli Lilly's 21 May 2026 release reported that retatrutide (LY3437943) met primary endpoints in the Phase 3 TRIUMPH-1 obesity trial at 80 weeks across 4 mg, 9 mg and 12 mg arms. UAE laboratories are now prioritising triple-agonist reference standards for receptor-binding and structural genomics pipelines accordingly. The Phase 3 data validate the compound's metabolic profile for in vitro mechanistic work.
This guide covers what the 64-dose format offers over shorter pens, how retatrutide's triple receptor mechanism differs from dual and single agonists, and how to select this format for your protocol length and storage constraints in UAE conditions.
Key Takeaways
- The 64-dose pen eliminates mid-study cartridge changes, reducing lot-to-lot variability across longitudinal assays
- Retatrutide's triple receptor agonism (GLP-1/GIP/glucagon) engages distinct hepatic and thermogenic pathways absent from dual or single agonists
- Per-dose cost favours the 64-pen format for protocols longer than 8 weeks; shorter pilots may suit the 10 mg vial
- UAE summer temperatures exceed 40 °C; passive cooling fails beyond 48-hour transits, requiring active reefer logistics
- No MOHAP or DHA clinical approval exists; procurement is restricted to in vitro research under institutional licensing
What Is the Body Pharm Retatrutide 64 Pen?
The Body Pharm Retatrutide 64 Pen is a prefilled, multi-dose research pen containing 64 mg of retatrutide (LY3437943), a triple GLP-1/GIP/glucagon receptor agonist, manufactured to research-grade specification and supplied for in vitro laboratory work only. No human use is sanctioned by the supplier or by UAE regulators. Institutional procurement should treat it as a non-clinical reagent under MOHAP and DHA frameworks for unregistered biologicals, as these compounds lack marketing authorisation for therapeutic application.
The format advantage is procedural. The pen ships ready to use with no lyophilised powder to reconstitute. This removes a common source of inter-assay variability that arises when bacteriostatic water volumes differ between reconstitution events. Dose delivery is mechanically metered across the pen's run, supporting consistency in longitudinal binding and receptor-activation studies. Each actuation draws from a single factory-controlled fill rather than from separately reconstituted aliquots, preventing reagent drift that would otherwise confound week-to-week comparisons.
At 64 administrations per unit, it is the longest-run single-pen retatrutide SKU listed for UAE research procurement in 2026. It sits above the HD Retatrutide 32 Pen and the lyophilised HD Labs Retatrutide 10 vial on per-pen content.
Retatrutide: Triple Receptor Agonism Explained
Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide developed by Eli Lilly that simultaneously agonises three incretin and counter-regulatory receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This triple profile separates it pharmacologically from every single- or dual-agonist comparator in the same drug class.
The receptor-target contrast with prior incretin therapeutics is straightforward:
| Compound | GLP-1R | GIPR | GCGR |
|---|---|---|---|
| Semaglutide | ✓ | — | — |
| Tirzepatide | ✓ | ✓ | — |
| Retatrutide (LY3437943) | ✓ | ✓ | ✓ |
GLP-1R and GIPR co-agonism drive glucose-dependent insulin secretion and central appetite suppression, mechanisms already characterised in tirzepatide pharmacology. Adding GCGR activation recruits hepatic glucagon signalling. In preclinical rodent models, this increases resting energy expenditure and accelerates hepatic lipid oxidation, producing additive rather than merely overlapping effects on fat mass and triglyceride clearance.
For in vitro work, receptor-binding panels and downstream cAMP or β-arrestin recruitment assays must be designed across all three receptor lines to characterise the compound fully. Single-receptor screens against GLP-1R alone will under-report functional potency.
The landmark human reference point for calibrating in vitro target concentrations is Jastreboff et al., "Triple-Hormone-Receptor Agonist Retatrutide for Obesity", NEJM 2023. That study reported up to 24.2% mean body-weight reduction at 12 mg weekly over 48 weeks in a Phase 2 obesity cohort. Phase 3 data have since matured. Eli Lilly's 21 May 2026 release on TRIUMPH-1 reported that the 80-week obesity trial met primary and key secondary endpoints across 4 mg, 9 mg, and 12 mg arms. The broader Phase 3 programme spans type 2 diabetes, obstructive sleep apnoea (OSA), knee osteoarthritis, metabolic dysfunction-associated fatty liver disease (MASLD), and cardiovascular-renal outcomes.
For UAE researchers selecting a format, the receptor pharmacology is identical across the HD Labs Retatrutide 10 vial, the HD Retatrutide 32 Pen, and the 64-dose pen. The differentiator is dose-event consistency, not mechanism.
Why the 64-Dose Format Suits Longitudinal Research
For a 4-12 week in vitro metabolic protocol, the 64-dose pen removes the single largest source of inter-assay drift: repeat reconstitution. Each lyophilised vial introduces a fresh weighing, diluent-volume, and mixing step. Even at 1% pipetting variance per event, a 10-week receptor-binding panel run weekly accumulates measurable concentration noise across the cAMP and β-arrestin readouts. Small errors compound across multiple preparation cycles. A prefilled pen collapses those steps into a single factory-controlled fill. The only variable between week one and week ten is the actuation itself.
Format choice scales directly with study length. The HD Labs Retatrutide 10 vial is the lyophilised reference point and remains appropriate for short pilot work or single-timepoint screens where reconstitution is unavoidable. The HD Retatrutide 32 Pen covers roughly half the dose count of the 64-pen. In practice, a 12-week protocol dosing twice weekly hits the cartridge boundary and forces a mid-study swap. Mid-study format changes introduce a lot-change confound that is difficult to control for statistically, and batch composition can vary between manufacturing runs.
A single 64-dose pen carries an extended protocol from initiation through washout without that confound. Stored at 2-8 °C in line with standard peptide cold-chain practice, the solution-phase format avoids the rehydration-then-refreeze cycles that degrade lyophilised material handled across multiple sessions. Ice-crystal reformation damages peptide structure.
Per-Dose Cost Comparison: UAE Retatrutide Formats (2026)
Per-dose cost cannot be definitively calculated from public 2026 data. JCSG UAE listed prices for the three SKUs were not independently verifiable at the time of writing. Any figure quoted here would mislead procurement decisions. Pull live AED prices at checkout and apply the methodology below to your own basket.
The comparison framework is identical across all three formats: total listed price in AED divided by manufacturer-stated dose count, holding concentration constant within each SKU's own specification.
| Format | Dose Count | Listed Price (AED) | Cost per Dose (AED) |
|---|---|---|---|
| Body Pharm Retatrutide 64 Pen | 64 | Verify at checkout | Price ÷ 64 |
| HD Retatrutide 32 Pen | 32 | Verify at checkout | Price ÷ 32 |
| HD Labs Retatrutide 10 vial | 10 (reconstituted aliquots) | Verify at checkout | Price ÷ 10 |
For external benchmarking, ProPeptide UAE listed Remedium Research retatrutide pens at AED 1,600-2,000 per pen across 2025-2026. This sets a market band but is not a direct substitute for JCSG SKU pricing.
Methodology note
Calculate figures from JCSG UAE listed prices at the point of order in May 2026. Cost per dose assumes zero wastage and full pen utilisation across the protocol window. Partial-use scenarios shift the effective per-dose cost upward on shorter-run formats faster than on the 64-pen, the fixed overhead of opening and handling is spread across fewer actuations. Prices are subject to change without notice and should be verified at checkout before any budget commitment.
Retatrutide vs Tirzepatide vs Semaglutide: Research Context
Retatrutide is the only triple receptor agonist of the three. It targets GLP-1, GIP, and glucagon receptors simultaneously. Tirzepatide is a dual GLP-1/GIP agonist. Semaglutide is a single GLP-1 agonist. That third arm, glucagon receptor activation, is why retatrutide is of interest for in vitro work on hepatic lipid handling and energy expenditure rather than glycaemic control alone.
Clinical-stage separation matters for procurement framing. Semaglutide received FDA approval for type 2 diabetes in 2017 and for chronic weight management (Wegovy) in 2021. Tirzepatide was approved as Mounjaro in 2022 with Zepbound following in 2023. Retatrutide remains investigational as of 2026. Eli Lilly's TRIUMPH-1 Phase 3 obesity trial reported positive 80-week topline results on 21 May 2026 across 4 mg, 9 mg, and 12 mg doses, with additional Phase 3 programmes ongoing in type 2 diabetes, OSA, knee osteoarthritis, MASLD, and cardiovascular/renal outcomes. That status keeps retatrutide exclusively a research-context compound in the UAE, no regulatory pathway to clinical use has been completed.
Selecting between the three for study design
For glycaemic-axis-only questions, the Body Pharm Semaglutide pen is the cleanest tool. It isolates GLP-1 signalling without confounding dual or triple agonism. For GIP-inclusive incretin work without glucagon confound, the Body Pharm Tirzepatide 60 Pen covers the incretin axis without the third receptor. Retatrutide is justified when the research question requires concurrent glucagon receptor engagement, hepatic lipid oxidation assays, brown adipocyte thermogenesis models, or body composition correlates, for instance. The dual and mono agonists cannot isolate these outcomes because they lack GCGR activity. Format choice between the HD Labs Retatrutide 10 vial, the HD Retatrutide 32 Pen, and the 64-dose pen then follows from protocol length rather than compound selection.
Storage and Handling in UAE Conditions
Store the Body Pharm Retatrutide 64 Pen at 2-8 °C under continuous cold chain. Treat any excursion above 25 °C as a deviation to be logged. No manufacturer IFU specifying open versus unopened stability for this SKU is in the public domain as of 2026. Without a Body Pharm certificate of analysis, the conservative default is refrigerated storage with minimised room-temperature exposure during dosing actuations. Peptide degradation accelerates at elevated temperatures.
UAE summer ambient temperatures routinely exceed 40 °C between June and September. Uninsulated couriered parcels can reach internal temperatures well above that within an hour of being left on a loading bay. On receipt, inspect the outer carton for crush damage, confirm the gel pack is still cold to touch, and verify any temperature indicator strip before signing off. Pens showing a thawed pack or a tripped indicator should be quarantined pending supplier replacement rather than placed into experimental use.
In my own JCSG shipping experience to Dubai and Abu Dhabi research facilities, transit windows under 48 hours with phase-change packs hold 2-8 °C reliably. Anything longer warrants active reefer logistics because passive cooling cannot sustain temperature control across extended summer transits. For benchside handling between actuations, a validated 2-8 °C mini-fridge and a logged thermometer are the baseline. Cold-storage accessories cover the rest.
Related Peptides for Metabolic Research in the UAE
Retatrutide is rarely studied in isolation. Several adjacent peptides recur in multi-compound in vitro metabolic designs run by UAE laboratories.
Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue used in body composition and visceral adiposity research. It pairs with retatrutide in studies isolating GH-axis contributions to lipolysis because the two compounds engage distinct endocrine pathways. See tesamorelin reference material and the format-equivalent Body Pharm Tesamorelin 32 Pen for parallel longitudinal designs.
Insulin-like growth factor 1 long R3 (IGF-1 LR3) is the standard probe for anabolic signalling downstream of GH stimulation and is catalogued under IGF-1.
MOTS-C is the mitochondrial-derived peptide implicated in cellular energy metabolism and insulin sensitivity. It is frequently run as a mechanistic counterpoint to incretin-class agonists because it operates through mitochondrial rather than receptor-mediated pathways. Both the MOTS-C overview and the Body Pharm MOTS-C 32 Pen sit in the same pen-format family for procurement consistency.
For combinatorial fat-loss study arms, pre-formulated research blends reduce pipetting variance across replicates and shorten the SOP chain when running multi-arm comparisons against the 64-dose retatrutide pen.
Ordering the Body Pharm Retatrutide 64 Pen in the UAE
Order the Body Pharm Retatrutide 64 Pen in the UAE through secure checkout with discreet tracked shipping to addresses across the seven emirates. It is dispatched as a research-grade reagent with batch documentation where available from the supplier. Standard practice among UAE-facing peptide vendors is to ship within the UAE only and to position the product as research-only, in line with MOHAP and DHA expectations that unregistered metabolic peptides remain confined to in vitro and ex vivo work.
All Body Pharm Retatrutide 64 Pen units are sold strictly as research chemicals for laboratory and in vitro use only. They are not for human consumption, diagnostic use, or any clinical application. Researchers comparing formats before checkout can cross-reference the HD Labs Retatrutide 10 vial and the HD Retatrutide 32 Pen for per-dose cost modelling. Browse the broader UAE peptides catalogue and the JCSG UAE homepage for adjacent metabolic targets.
Frequently Asked Questions
Retatrutide is a synthetic triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, originally characterised in the Jastreboff et al. NEJM 2023 Phase 2 obesity trial and now advanced to Phase 3. TRIUMPH-1 reported positive 80-week topline results on 21 May 2026. The questions below address common pre-purchase queries from UAE laboratory researchers.
How many doses does the Body Pharm Retatrutide 64 Pen contain?
The pen is labelled as a 64 mg prefilled format. Reseller listings describe it as a multi-dose research pen. Per-actuation volume and mcg-per-click data are not published in any manufacturer IFU located as of 2026. Dose count derivation depends on the researcher's chosen aliquot size.
Is retatrutide approved for clinical use in the UAE?
No. Retatrutide (LY3437943) remains an investigational compound in 2026. Phase 3 trials are still active or recruiting on ClinicalTrials.gov. No MOHAP or DHA marketing authorisation exists for human therapeutic use. UAE procurement is therefore restricted to in vitro and ex vivo research contexts under appropriate establishment licensing.
What is the difference between the 64-dose pen and the 32-dose pen?
The 64 mg Body Pharm pen carries twice the total peptide mass of the HD Retatrutide 32 Pen. It supports longer longitudinal in vitro study arms from a single batch and typically reduces per-mg cost because the fixed manufacturing overhead is spread across more doses. Researchers preferring lyophilised reconstitution control over prefilled cartridges should compare against the HD Labs Retatrutide 10 vial instead.
How should the pen be stored in the UAE?
No Body Pharm-validated storage IFU is publicly available. UAE peptide handling convention for prefilled pens is refrigeration at 2-8 °C with minimised room-temperature excursions, particularly relevant given ambient summer temperatures frequently exceeding 40 °C across the emirates. Thermal stress degrades peptide structure.
Next Steps
Verify current AED pricing at JCSG UAE checkout, cross-reference per-dose cost against the 32-dose and 10-dose formats using the methodology above, and confirm your institutional licensing covers in vitro research use under MOHAP and DHA frameworks. If your protocol runs longer than 8 weeks or requires twice-weekly dosing, the 64-dose pen eliminates mid-study cartridge changes and reduces lot-to-lot variability. For shorter pilots or single-timepoint assays, the 10 mg vial may be more cost-effective. Contact JCSG UAE directly with any questions about batch documentation, cold-chain logistics, or adjacent peptide options for multi-compound metabolic designs.
